Practice patterns for spasticity management with phenol neurolysis
DOI:
https://doi.org/10.2340/16501977-2239Keywords:
phenol, neurolysis, spasticity.Abstract
Objective: To present practice patterns for phenol neurolysis procedures conducted for spasticity management. Design: A retrospective review of 185 persons with spasticity who underwent phenol neurolysis procedures (=93) at an academic rehabilitation hospital and clinic. Patient demographics, concomitant spasticity treatments, and procedure relevant information were collected. Results: The cohort included 71. 9% males and 61. 6% inpatient procedures. Neurological diagnoses included stroke (41. 0%), traumatic brain injury (28. 6%) and spinal cord injury (24. 3%). Musculoskeletal diagnoses included spastic hemiplegia or paresis (51. 3%), tetraplegia (38. 4) and paraplegia (9. 2%). At the time of phenol neurolysis, most patients (77. 5%) received concomitant pharmacological treatments for spasticity. Injection guidance modalities included electrical stimulation and ultrasound (69. 3%) or ultrasound only (27. 3%). A mean of 3. 48 ml of phenol were injected per nerve and 10. 95 ml of phenol were used per procedure. Most commonly injected nerves included the obturator nerve (35. 8%) and sciatic branches to the hamstrings and adductor magnus (27. 0%). Post-phenol neurolysis assessment was recorded in 54. 9% of encounters, in which 84. 5% reported subjective benefit. Post-procedure adverse events included pain (4. 0%), swelling and inflammation (2. 7%), dysaesthesia (0. 7%) and hypotension (0. 7%). Conclusion: Phenol neurolysis is currently used to reduce spasticity for various functional goals, including preventing contractures and improving gait. Depending on the pattern of?spasticity displayed, numerous peripheral nerves in the upper and lower extremities can be targeted for treatment with phenol neurolysis. Further research into its role in spasticity management, including studies exploring its cost-effectiveness and pharmacological and side-effects compared with other treatment options are needed.Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Jay Karri, Manuel F. Mas, Gerard Francisco E., Sheng Li
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.